Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Status:
Not yet recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase I-II dose-escalation and expansion study designed to define the
recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+
ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term)
safety, and efficacy of brigatinib in these children.